Cargando…

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner

PURPOSE OF REVIEW: This review focuses on the feasibility of combining Bruton’s tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munoz, Javier L., Wang, Yucai, Jain, Preetesh, Wang, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Lymphomas (T Hilal, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474429/ https://www.ncbi.nlm.nih.gov/pubmed/35596920 http://dx.doi.org/10.1007/s11912-022-01286-0

Ejemplares similares

Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider’s Perspective
por: Granroth, Ginna, et al.
Publicado: (2022)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice
por: Weber, Theresa, et al.
Publicado: (2022)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma
por: Pinnix, Chelsea C., et al.
Publicado: (2018)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Advances in the assessment of minimal residual disease in mantle cell lymphoma
por: Jung, Dayoung, et al.
Publicado: (2020)

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2022)

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
por: Bouard, Louise, et al.
Publicado: (2022)

Smudge cells in CD200(+), TP53 mutated leukemic mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2022)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

Follicular lymphoma genomics
por: Kumar, Emil, et al.
Publicado: (2019)

Treatment of high-risk follicular lymphoma
por: Jurczak, Wojciech
Publicado: (2019)

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022)

Primary Mediastinal Large B-cell Lymphoma
por: Dabrowska-Iwanicka, Anna, et al.
Publicado: (2014)

Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
por: Hill, Holly A., et al.
Publicado: (2023)

Novel prognostic tools that identify high-risk follicular lymphoma
por: Luminari, Stefano
Publicado: (2019)

The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
por: Chu, Yaya, et al.
Publicado: (2022)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors
por: Gerdtsson, Anna Sandström, et al.
Publicado: (2022)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Primary CNS Lymphoma
por: Phillips, Elizabeth H., et al.
Publicado: (2014)

Molecular classification of aggressive B-cell lymphoma
por: Bojarczuk, Kamil, et al.
Publicado: (2019)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_229ogcuoeu2s9e47hg4ehnb7tf